2014 Alternative Careers in Science – Speed Networking Event

Tuesday, April 22, 2014, 6:30 to 9:00 PM
BU School of Medicine, Hiebert Lounge, 72 East Concord St, Boston, MA 02118

About the Panelists

ACADEMIA AND TEACHING

Heather Felton, M.S., Sc.D.
Administrative Manager for Biology and Neuroscience, Brandeis University

Heather Felton is the Administrative and Operations Manager for the Department of Biology and the Interdepartmental Neuroscience Program at Brandeis University. She oversees the day-to-day operations of the research and academic missions of both departments. Heather has worked on the Brandeis campus for 14 years; 7 years in her current position and 7 years as a lab manager in a Biology/HHMI laboratory. Most recently she has been instrumental in designing, developing and implementing an accounting shadow system & numerous databases that seek to streamline business processes for the University.

Heather earned a Sc.D. in Applied Anatomy and Physiology from Boston University, a M.S. in Exercise Physiology from Boston University, and a B.S. in Neuroscience, summa cum laude with honors, from Hamilton College.

Nick Andrews, Ph.D.
Instructor & Manager of Behavioral Core Facilities, Boston Children's Hospital, Harvard Medical School

Nick is an experienced in vivo neuroscientist having worked in academia and the pharmaceutical industry for 24 years. He has managed groups working on drug discovery projects for various CNS disorders using behavioural, neurochemical and physiological techniques. He has a B.Sc. in Biomedical Sciences at the University of Bradford, UK, and a Ph.D. under the direction of Professor Sandra File from Guy's Hospital, studying the serotonergic mediation of anxiety during withdrawal from chronic diazepam treatment. He completed a 3 year post-doc before moving to work at Parke Davis in Cambridge, UK. After 5 years at PD he spent 7 years at Organon in Scotland before moving to Pfizer, Sandwich where he spent his last 3 years in industry. After leaving Pfizer he moved to take up a joint position at Boston Children's Hospital & Harvard Medical School where he currently manages 2 Core facilities (pain and neurodevelopmental behavior). He has published 31 papers, 6 reviews and 32 conference communications across a range of neurobiological subjects & has been an invited speaker at several conferences. He is the current Chair-elect to the Non-Human Species Special Interest Group, IASP, Associate Editor of Frontiers in Neuropharmacology & an active referee for several journals. His special areas of interest include behavioural pharmacology (relating to studies of pain, anxiety, depression,

psychosis and cognition) & in vivo freely moving microdialysis of monoamines, amino acids, acetycholine and corticosterone.

BUSINESS DEVELOPMENT

Andrea Schievella, Ph.D.

Business Manager, Cancer Research Technology, Inc.

Andrea received her undergraduate degree in Biology at MIT and her Ph.D. from Harvard. After a three year post-doctoral fellowship in Genetics Institute's Small Molecule Drug Discovery department, Andrea joined then 10-person Variagenics, a startup company focused on personalized medicine founded by MIT biology professor David Housman. During her initial years at Variagenics, Andrea's roles included scientist, alliance manager and proposal writer. Subsequently, Andrea moved to business development, where she built alliances with pharmaceutical and biotechnology companies in the US and Europe. From May of 2004 to January of 2008, Andrea worked at MIT's Technology Licensing Office, licensing MIT, Whitehead Institute and Lincoln Lab technologies to both established and start-up companies. She now works at Cancer Research Technology, facilitating the commercialization of technologies developed with funding from the UK medical research foundation Cancer Research UK.

Stanley O. King II, Ph.D.

Business Development Associate, Wyss Institute

Stan is the Business Development Associate for the Wyss Institute for Biologically Inspired Engineering at Harvard University. He is responsible for assessing the commercial potential of the Institutes' technologies and determining the appropriate development and commercialization strategy. In this role, he performs market research and identifies potential licensees and industrial partners for each technology. He also negotiates options, confidentiality, inter-institutional agreements, exclusive and non-exclusive licenses and collaboration agreements. Stanley has experience in all aspects of commercializing and translating life science research innovations. Prior to the Wyss he was a Technology Licensing Associate at the Massachusetts Institute of Technology (MIT) Technology Licensing Office (TLO) and he began his licensing career at the University of Virginia Patent Foundation. In his previous positions, he managed patent portfolios that consisted of over 600 active cases, negotiated and executed over 30 licensing deals with both start-up and established life science and medical device companies, and advised investigators on both patent and business strategy. In 2012 he received an MIT Infinite Mile Award from the MIT Vice President for Research for the contributions he made at the TLO that helped MIT carry out its mission. Stanley holds a Ph.D. in Neuroscience and Behavior from the University of Virginia and a BS from Florida A & M University.

CONSULTING

Regina Au, M.B.A.

Strategic Marketing Consultant, BioMarketing Insight

Regina Au is a strategic marketing consultant at BioMarketing Insight with 20 + years' experience in the biotechnology, pharmaceutical, medical device, and diagnostic industries. She helps companies evaluate their technology upfront by conducting an in-depth business due diligence to de-risk the product development process. This ensures that the technology is the right product for the right market in meeting a critical unmet need and that the market potential for the product meets the business goals of the company. She will translate these unmet needs into a product profile or specification. Ms. Au then develops marketing strategies to ensure a successful product launch. Ms. Au also serves as an advisor for the Massachusetts Technology Transfer Center Platform Meetings with entrepreneurs. Her expertise is in various therapeutic areas such as cardiology, interventional cardiology, infectious disease, immunology, surgery, gastroenterology, and pulmonology. Prior to BioMarketing Insight she worked for companies such as Merck & Co., Genzyme Corp., NMT Medical, and St. Jude Medical in various positions of increasing responsibility in marketing and sales. She had P&L responsibility in managing a number of multimillion dollar product lines and has experience in upstream and downstream marketing including strategic marketing, product development, market development, product launches, and product management. Her background includes an M.B.A. in Marketing from the University of Connecticut, a Microbiology degree from the University of Michigan and a Masters in International Management from Thunderbird School of Global Management.

COMPETITIVE INTELLIGENCE

Anne-Elise Tobin, Ph.D.

Senior Business Insights Analyst, Pharmaview Team, CNS and Pain, Decision Resources Group

Anne-Elise is an analyst at Decision Resources Group, where she currently supports her company's commercial research product suite, Pharmaview, which analyzes the commercial and therapeutic strategy of the leading pharmaceutical companies. She focuses on drug development within central nervous system disorders, ophthalmology, and pain. She has previously served as a disease-specific expert conducting primary research and market analysis for drug development in schizophrenia and migraine. Her research includes evaluating company financial reports, interviewing experts, surveying physicians and payers, and analyzing clinical trial data to assess whether therapies in development will meet the needs of patients and physicians and be commercially successful. Prior to joining Decision Resources, she was a postdoctoral researcher in neuroscience at Brandeis University, where she identified mechanisms underlying the variable response of neural networks to neuromodulation. During her time at Brandeis, she founded the Brandeis University Postdoctoral Organization to facilitate interdisciplinary scientific discourse, career development, and networking events. Anne-Elise holds a Ph.D. in neuroscience from Emory University.

ENGINEERING

Allison Hall

Engineering Supervisor, Terumo Cardiovascular Systems

Allison Hall is an Engineering Supervisor at Terumo Cardiovascular Group, a global leader in the development and production of medical devices for cardiac surgery. Currently, Allison leads the engineering department responsible for supporting the manufacture of Terumo CV Group's custom perfusion circuits product line, which are the disposable systems used to circulate, oxygenate and monitor a patient's blood during cardiopulmonary bypass surgery. In this role, Allison is responsible for the planning and management of the department's efforts on a variety of projects, including product, manufacturing process, and quality systems improvements. Prior to assuming her current role, Allison was the project manager for a corporate initiative to convert the manufacturing documentation process at two Terumo factories from a paper-based system to an electronic documentation system that uses manufacturing execution system software. Allison graduated in 2005 with a Bachelor's degree in Mechanical Engineering from MIT.

ENTREPRENEURSHIP

Lauren Celano

Co-Founder and CEO, Propel Careers

Lauren Celano is the co-founder and CEO of Propel Careers, a life science search and career development firm focused on connecting talented individuals with entrepreneurial life sciences companies. Propel works with current leaders and actively cultivates future leaders through full time placement, internships, mentoring, career coaching, and networking. Propel Careers is engaged across all areas of life sciences, including therapeutics, medical devices, healthcare IT, diagnostics, consulting, venture capital, and investment banking. Prior to Propel Careers, Lauren was a senior account manager for SNBL USA where she worked with emerging biotech companies in Europe, Asia, and the US to help characterize and advance their drug molecules. Prior to SNBL USA, she held business development positions with Aptuit and Quintiles, where she focused on IND enabling studies to advance therapeutics from discovery into the clinic. Earlier in her career, Lauren held positions as a marketing manager and account manager at Absorption Systems, where she was responsible for managing life sciences companies in the northeastern United States. She has a B.S. in Biochemistry and Molecular Biology from Gettysburg College and an M.B.A. with a focus in the health sector and entrepreneurship from Boston University. Lauren is on the Board of MassBioEd and she also serves on the programming committee of the Capital Network.

NON-PROFIT

Meagan Lizarazo

Vice President, iGEM Foundation

Meagan Lizarazo is the Vice President of Operations of the iGEM Foundation. The iGEM Foundation is an independent nonprofit dedicated to education and competition, advancement of synthetic biology, and the development of open community and collaboration. It fosters scientific research and education through organizing and operating the iGEM Competition, the premier student synthetic biology competition. Meagan has been involved with iGEM since 2005, beginning with research on automated assembly, followed by managing the iGEM competition. She now directs operations of the iGEM program as well as operations of the iGEM Foundation nonprofit organization. Meagan received her B.A. in Biological Sciences from Wellesley College.

HUMAN RESOURCES

Dave Anderson

R&D Recruiting Manager, EMD Serono

Dave is currently the R&D Talent Acquisition Manager for EMD Serono. His areas of focus include Immuno-Oncology, Immunology and Autoimmunity, Inflammation and Remodeling, Orphan and Genetic Diseases, and Academic/Industry partnered research. Dave also brings bench experience from notable research institutions including Columbia University, BWH/MGH, Genzyme, and Biogen Idec. As an undergrad, he studied Biology at Clarkson University and Dave completed the ALM Biotechnology Professional Master's program at Harvard University.

MEDICAL AFFAIRS

Yelena Wetherill

Director, Oncology Health Systems, Medical Affairs, Merck

Prior to joining Merck, Yelena was a Clinical Research Scientist at ARIAD Pharmaceuticals, Cambridge, MA. At ARIAD, was on Clinical Research and Development team and worked on all aspects of clinical trial development, design and execution of Phase I through Phase III studies in oncology/hematology. From 2011 to 2013, Yelena was with SANOFI Oncology, Cambridge, MA, where she held lead positions in regulatory Medical Writing, Clinical Documentation, and in scientific publications, Global Medical Affairs. Prior to SANOFI, Yelena was a clinical science liaison in a local oncology biotech and a senior oncology scientific writer with at a medical education agency. Yelena also served as an Adjunct Research Investigator at Harvard Global Equity Initiative, Harvard University, MA, where she worked on the Global Task Force for Expanded Access to Cancer Care and Control in Developing Countries.

Yelena completed a multidisciplinary post-doctoral fellowship in breast cancer at Harvard Medical School, Dana-Farber Cancer Institute (2006-2010), funded by the National Service Research Award and Susan G. Komen Postdoctoral Research Award. Yelena received her Ph.D. degree in 2005 from the University of Cincinnati Medical School where she studied molecular mechanisms of androgen receptor signaling in advanced prostate cancer. She earned an honors B.Phil. in Neuroscience, Biological Sciences at the University of Pittsburgh Honors College.

Yelena is an ambassador with the Science Club for Girls and WEST: Advancing Women in the Enterprise of Science and Technology. She also leads volunteer efforts at Boston Hope Lodge and American Cancer Society's Making Strides against Breast Cancer Walk.

MEDICAL WRITING

Effie Tzameli

Editor, Cell Press

Effie Tzameli got her Ph.D. from Boston University School of Medicine in Molecular Biology/Biochemistry. Then she moved to MGH/Harvard Medical School where she joined the laboratory of David Moore for a post-doc with focus on nuclear hormone receptors. Upon completion of her postdoctoral she decided to move to the metabolism field and was appointed Instructor in Medicine at Beth Israel and HMS under the mentorship of Jeff Flier. There she worked on a variety of projects relating to obesity and diabetes. Her work has been published in several of high profile journals including MCB, JCI, Cell Metabolism, Nature and Nature Medicine.

In 2011 she moved to Cell Press to run one of the Reviews journals, Trends in Endocrinology and Metabolism. As an Associate Editor she spends her time developing strategic direction and vision for the journal which includes commissioning cutting edge review articles by leaders in the field, interacting with authors and reviewers and taking manuscript through the peer review process, networking with the scientific community at meetings, organizing conferences and managing a variety of projects.

PATENT LAW

Donna T. Ward, Ph.D., J.D.

Patent Attorney, Intellectual Property

Dr. Ward has over fifteen years of law firm and in-house counsel experience. She has legal and technical expertise representing both established and emerging commercial organizations in biotechnology areas that include protein and nucleic acid chemistry, drug delivery systems and devices. In addition, Dr. Ward has represented clients in the alternative energy (green tech) fields, the mechanical arts, and pharmaceuticals.

From leading-edge biotech companies founded on Nobel prize winning science to startups focusing on environment-saving technologies, Dr. Ward specializes in, and has managed the creation, growth and competitive positioning of, intellectual property portfolios covering some of the most innovative and complex areas of scientific discovery.

Dr. Ward holds a BS in Biology from Cumberland University and a Ph.D. in Biochemistry from the University of Kentucky, College of Medicine. She received her postdoctoral training in the field of Mass Spectroscopy in the Chemistry Department at Vanderbilt University.

She is the founder of DT Ward, PC an intellectual property firm with locations in Groton and Cambridge MA specializing in life science start-ups.

She is a member of the state bar of the Commonwealth of Massachusetts and is registered to practice before the United States Patent and Trademark Office (USPTO).

Chelsea Loughran, J.D., M.P.H

Associate, Wolf, Greenfield & Sacks, P.C.

Chelsea Loughran is a litigation associate at the intellectual property law firm Wolf, Greenfield & Sacks, P.C. She routinely works in the areas of trademark, trade dress, patent, and copyright litigation. Chelsea graduated from Brown University in 2004 with a degree in Biology, and from Northeastern University and Tufts University School of Medicine in 2008 with a dual degree in law and public health (J.D., M.P.H.). Chelsea and her team successfully defended world-renowned mouse repository and research institute, the Jackson Laboratory, in two successive patent litigation suits brought in 2008 and 2010. Since then, Chelsea has represented a wide range of clients in various technology areas, including Keurig, Incorporated, the pioneer of single-serve coffee brewing systems and BTG International Inc., a manufacturer of antibody-based snake antivenoms for the treatment of rattlesnake envenomation. Chelsea maintains an active pro bono docket and is a member of a variety of professional and civic organizations, including the Association for University Technology Managers (AUTM), The Boston Bar Association - Volunteer Lawyers' Project, the Massachusetts LGBTQ Bar Association, the Boston Patent Law Association and the Massachusetts Women's Bar Association. She also sits on the Board of Directors for the Legal Advocacy Resource Center and works in strategic development for Greater Boston Legal Services.

PROJECT MANAGEMENT

Cherié L. Butts, Ph.D.

Associate Director of Immunology Research, Biogen Idec

Dr. Butts is Associate Director of Immunology Research at Biogen Idec (Cambridge, MA). Her research interests include how factors produced in the microenvironment - especially steroid hormones - impact immunity and increase susceptibility to disease. Dr. Butts obtained undergraduate (chemistry) and master's (immunology) degrees from The Johns Hopkins University. Her pre-doctoral studies at UT MD Anderson Cancer Center focused on characterizing anti-tumor immune responses in patients with epithelial ovarian cancer. Seeing a connection between steroid hormone effects on immunity and the ability of immune cells to eliminate tumor cells, Dr. Butts chose to conduct her postdoctoral studies at the National Institutes of Health on deciphering hormonal regulation of immunity. She continued this work at the US Food & Drug Administration and also took on responsibilities evaluating drug and biologics applications. In her current position, Dr. Butts brings together her scientific expertise and drug/biologics review experience to facilitate movement of drug products aimed at treating autoimmune/inflammatory and fibrotic conditions through the pipeline. Her role as project manager includes facilitating project progress, assessing risk involved with different activities, and working with different groups within the organization to ensure key information is available to make critical decisions.

RESEARCH & DEVELOPMENT

Jennifer Marlowe, Ph.D.

Head of the Biochemical, Cellular and Molecular Toxicology, Novartis

Jenny is Head of the Biochemical, Cellular and Molecular Toxicology group in Cambridge (Discovery and Investigative Safety, Preclinical Safety, NIBR). Jenny began her career at Novartis in Investigative Toxicology in Basel, where she headed a laboratory focused on molecular mechanisms of carcinogenesis as well as epigenetic mechanisms of adverse drug effects. She transitioned in 2009 to Cambridge in order to initiate and head a new Molecular Toxicology group focused on molecular on- and off-target mechanisms of toxicity as well as understanding mechanisms of adverse effects of systemically delivered nucleic acid therapeutics. She also represents the Preclinical Safety organization as a Project Team Member for oncology and cardiovascular disease programs, functions as Science and Portfolio Manager for the Preclinical Safety Cardiovascular and Metabolism Disease Area Strategy Team, and leads global communications strategy for the Discovery and Investigative Safety group. Prior to joining Novartis, Jenny earned a Ph.D. in Molecular Toxicology, with an emphasis in cellular and molecular mechanisms of carcinogenesis, from the Department of Environmental Health Sciences at the University of Cincinnati. She also holds a Bachelor of Science degree in Zoology (Miami University, Oxford, Ohio)

Laura Zawadzke, Ph.D.

Principal Scientist, Constellation Pharmaceuticals

Education: Massachusetts Institute of Technology (Ph.D. in Biochemistry), Valparaiso University (BS in Chemistry)

Laura has been working in the field of epigenetic lead discovery at Constellation for over 2 years. Prior to that she acquired 15 years of pharmaceutical industry experience at Pfizer and Bristol Myers Squibb. Laura's research includes target evaluation, development and use of assays in both HTS and SAR efforts for enzymes, membrane receptors, and ion channels. In this arena she has led mechanistic studies for the biological evaluation of enzyme inhibitors as applied to drug discovery. Through her career, Laura has demonstrated extensive "hands-on" knowledge of biochemical and cellular in vitro pharmacological and chemical concepts and methods. Laura's specialties include enzymology, HTS and data analysis methods.

REGULATORY AFFAIRS

Gail Radcliffe, Ph.D.,

President, Radcliffe Consulting, Inc.

Gail E. Radcliffe, Ph.D. has more than 20 years' experience assisting medical device and diagnostics companies with technical assessment, marketing and clinical/regulatory issues. Gail founded Radcliffe Consulting in 1998 after having worked at GENE-TRAK, where she developed IVD assays for several infectious disease organisms including HIV, CMV, TB and Chlamydia and was responsible for instituting the clinical affairs group. She later joined Cytyc Corporation where she identified novel applications for the ThinPrep Processor and helped forge partnerships with other health care companies to expand product offerings.

As a consultant, Gail has provided assistance to start-up and established medical device companies with market research and business model selection (IVD vs. CLIA lab), regulatory strategy, quality systems development and clinical trial support. Consulting engagements have

encompassed a wide range of products including novel cutting edge digital pathology instruments, stem cell laser dissection devices, companion diagnostics, and multiplex molecular, POC and CLIA Waiver in vitro diagnostic tests.
Gail obtained a Ph.D. in Molecular Biology from Brown University and completed a post-doctoral fellowship in molecular immunology at the University of Massachusetts Medical School.
She is a member of the Regulatory Affairs Professional Society (RAPS), American Society of Microbiology (ASM) and Sigma Xi. She is on the Board of Trustees of the Massachusetts Biomedical Initiatives and acts as an advisor to several venture capital companies.

SALES & MARKETING

Courtney Mankus
Product Manager and Research Scientist, MatTek Corporation

Courtney began her career in science by obtaining her bachelor's degree in biochemistry from Clark University in Worcester, MA. During that time she was employed as an intern at ECI Biotech, working on the colorimetric detection of bacteria. Following graduation, Courtney went on to earn her Ph.D. in biochemistry from the Trinkaus-Randall lab at Boston University School of Medicine in 2009. She returned to ECI Biotech as a Senior Scientist and Project Manager upon completing her Ph.D. After several years, she moved on to her current position as Product Manager and Research Scientist with MatTek Corporation and has been there for just over 2 years.

Julie Meyer
Senior Strategic Account Manager, QIAGEN

Julie Meyer is a dedicated sales professional in life science and clinical markets. Julie has degrees in Biology and Psychology from the University of Rochester. Working at Roswell Park Cancer Institute, she deepened her knowledge of cancer biology and customer service by managing a core facility dedicated to gene expression research. Julie joined QIAGEN in November 2004 and is a Senior Strategic Account Manager. Each day scientists look for answers to complex questions – questions from basic research to clinical diagnostics. Julie offers her business acumen, knowledge base, professional network, and analytical skills as resources to her customers. Together Julie and her customers achieve beneficial solutions to questions, whether scientific or economic. Julie wins and maintains customer satisfaction, and forms strategic alliances to drive sustainable business for the long-term. You can find Julie at Pfizer, AstraZeneca, AbbVie, UMass Med, Boston University, Boston Medical Center, Dartmouth, and the University of Vermont. Outside of QIAGEN, Julie is a mentor through the Association for Women in Science. She is co-owner of Guerrilla Explorer Publishing, and celebrates a creative approach to life and work.

SCIENCE POLICY

Alice Pomponio
Head of Corporate Affairs--North America/International Science Affairs, AstraZeneca

Alice Lin Pomponio is Head of Corporate Affairs--North America/International Science Affairs for AstraZeneca. Her team works closely with scientific stakeholders in academia, government, and nonprofits to promote favorable external R&D environments and to proactively shape

AstraZeneca's global science policies. Prior to joining AstraZeneca in 2012, Alice was Senior Director of Global Policy Programs at Genzyme Corporation where she focused on international innovation, health, and trade policy issues affecting patient access to biologics and orphan drugs. Between 2000 and 2005 she served as Vice Consul and US Life Sciences and Healthcare Industry Advisor to the British Government with responsibility for US industry relations and strategic input into UK government life sciences initiatives. She previously worked at US Office of Management and Budget (OMB) with responsibility for the US Department of Energy (DoE) Human Genome Program management review. She conducted laboratory research at Viagene Inc. and the MIT Whitehead Institute and has held product pricing and reimbursement roles at Genzyme. Alice holds a Bachelor of Science in Biology from MIT and a Master's in Public Policy from Harvard University.

SOCIAL ENTERPRISE

Social enterprise is the application of business practices and models to providing goods or services that create social good.

Nina Dudnik

Founder and CEO, Seeding Labs

Nina Dudnik is the founder and CEO of Seeding Labs, a nonprofit organization ensuring that scientists in the developing world have the tools, training and network to pursue life-changing research. Nina decided at a very early age to become a scientist. Her interest in science, however, always had a humanitarian angle. After earning a Bachelor's in biochemistry from Brown University she worked in agricultural development with the Consultative Group for International Agricultural Research in Italy and in Cote d'Ivoire where she was a Fulbright scholar. During this time she worked in labs on three continents with scientists from every part of the world. While pursuing her Ph.D. in molecular biology at Harvard University she founded Seeding Labs to help this global community of scientists. To date Seeding Labs has provided over $2M in equipment and training and reached over 16,000 scientists in 21 countries. For her work with Seeding Labs, Nina has been named a 2010 PopTech Social Innovation Fellow and TED Fellow and received a 2012 Boston Business Journal 40 Under 40 award. Seeding Labs has been featured on National Public Radio's All Things Considered, in publications including the Boston Globe, The Kenyan Standard, Elle Magazine, and Chemical & Engineering News.

TECHNOLOGY TRANSFER

Erika Bechtold, Ph.D.

Licensing Associate, Tufts University

Erika Bechtold is a licensing associate responsible for working with senior staff to support faculty in Arts and Sciences and the School of Engineering. Erika recently completed a post-doctoral fellowship at MIT focusing on biological engineering of new tools for study of basic malaria parasite biology. She holds a B.S. in chemistry from Virginia Polytechnic Institute and State University (Virginia Tech) and a Ph.D. in chemistry from Wake Forest University.

Irene Abrams

Executive Director, Partners Healthcare Innovation, Massachusetts General Hospital

Irene is an Executive Director at Partners Healthcare Innovation, the organization responsible for commercializing technology from Massachusetts General Hospital, Brigham and Women's Hospital and other Partners' hospitals. Irene is responsible for developing the commercial innovation capability at Partners and increasing its application in new products benefiting patients. She manages the team responsible for licensing discoveries from MGH labs. Prior to joining Partners, Irene was the Associate Provost for Innovation at Brandeis University and founded the Brandeis Virtual Incubator. Prior to joining Brandeis in 2006, Irene was a Senior Technology Licensing Officer at MIT, where she focused on licensing biotech inventions for MIT, the Whitehead Institute and the Broad Institute. Irene did her undergraduate work at the University of Pennsylvania and her graduate work at the Johns Hopkins University and at MIT Irene is the past President of the Massachusetts Association of Technology Transfer Offices, the founder of T3, a networking organization for technology licensing offices from small New England research institutions, and an Associate Vice President of the Association of University Technology Managers.

Monique Yoakim-Turk, Ph.D.

Partner, Technology Development Fund, Children's Hospital

Monique joined TIDO of Boston Children's Hospital in 2000. As Partner, Technology Development Fund, Monique created the Boston Children's Hospital Technology Development Fund (TDF), which launched in March of 2009.

In her previous role as Senior Licensing Manager, Monique handled technologies in the therapeutic, diagnostic, and medical device arenas, closed significant deals in licensing and sponsored research, and established creative collaborations with industry partners.

Prior to Boston Children's, Dr. Yoakim-Turk was a post-doctoral fellow at the Beth Israel Deaconess Medical Center in the laboratory of Dr. Benjamin Neel. She holds a Ph.D. in Biochemistry from the Tufts University, Sackler School of Graduate Biomedical Sciences. Monique has authored and co-authored 9 peer reviewed publications. She also holds a B.S. and an M.S. in Biology from the University of Massachusetts.